Premium
Infant botulism in Australia: availability of human botulinum antitoxin for treatment
Author(s) -
May Meryta L A,
Corkeron Michael A,
Stretton Mark
Publication year - 2010
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2010.tb04073.x
Subject(s) - alma mater , intensivist , medicine , antitoxin , pediatrics , library science , surgery , intensive care medicine , intensive care , biology , microbiology and biotechnology , dura mater , computer science , toxin
We report the first Australian case of treatment of infant botulism with a human botulinum antitoxin developed in the United States by the California Department of Public Health. Our patient's clinical improvement was rapid, and although the product is expensive, cost-analysis supports the economical viability of its use. In future cases of suspected infant botulism, we recommend that Australian clinicians promptly obtain and administer this antitoxin to their patient.